JPWO2018073393A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2018073393A5 JPWO2018073393A5 JP2019520685A JP2019520685A JPWO2018073393A5 JP WO2018073393 A5 JPWO2018073393 A5 JP WO2018073393A5 JP 2019520685 A JP2019520685 A JP 2019520685A JP 2019520685 A JP2019520685 A JP 2019520685A JP WO2018073393 A5 JPWO2018073393 A5 JP WO2018073393A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- antigen
- protein
- molecule
- family
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410187P | 2016-10-19 | 2016-10-19 | |
| US62/410,187 | 2016-10-19 | ||
| DKPA201770240 | 2017-03-31 | ||
| DKPA201770240 | 2017-03-31 | ||
| PCT/EP2017/076800 WO2018073393A2 (en) | 2016-10-19 | 2017-10-19 | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2019531742A JP2019531742A (ja) | 2019-11-07 |
| JP2019531742A5 JP2019531742A5 (https=) | 2023-01-25 |
| JPWO2018073393A5 true JPWO2018073393A5 (https=) | 2023-01-25 |
| JP7236380B2 JP7236380B2 (ja) | 2023-03-09 |
Family
ID=60268352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520685A Active JP7236380B2 (ja) | 2016-10-19 | 2017-10-19 | 治療に適したｔａｌエフェクターヌクレアーゼ（ｔａｌｅｎ）改変同種異系細胞 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230138915A1 (https=) |
| EP (1) | EP3529265A2 (https=) |
| JP (1) | JP7236380B2 (https=) |
| AU (1) | AU2017347685B2 (https=) |
| CA (1) | CA3041039A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113015750A (zh) | 2018-11-07 | 2021-06-22 | 克里斯珀医疗股份公司 | 抗liv1免疫细胞癌症疗法 |
| CA3185455A1 (en) * | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| CN117129690B (zh) * | 2023-09-26 | 2025-06-06 | 杭州师范大学 | Grhl1在her2-乳腺癌诊断及预后评估中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102437522B1 (ko) * | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| WO2014191128A1 (en) * | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| MX373460B (es) * | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| WO2016124765A1 (en) | 2015-02-06 | 2016-08-11 | Cellectis | Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles |
| KR20260048600A (ko) | 2015-03-27 | 2026-04-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 변형된 t 세포 및 이의 제조 및 사용 방법 |
| CN117070468A (zh) * | 2015-10-05 | 2023-11-17 | 精密生物科学公司 | 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞 |
| IL262365B2 (en) * | 2016-04-15 | 2024-11-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins ICOS ligand variants and uses thereof |
-
2017
- 2017-10-19 EP EP17794690.2A patent/EP3529265A2/en active Pending
- 2017-10-19 JP JP2019520685A patent/JP7236380B2/ja active Active
- 2017-10-19 US US16/340,412 patent/US20230138915A1/en active Pending
- 2017-10-19 AU AU2017347685A patent/AU2017347685B2/en active Active
- 2017-10-19 CA CA3041039A patent/CA3041039A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273201B1 (en) | Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | |
| JP2025037871A5 (https=) | ||
| JPWO2021188599A5 (https=) | ||
| Lin et al. | Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen | |
| IL273948B2 (en) | Compositions and methods for selective protein degradation | |
| JP2020517263A5 (https=) | ||
| RU2018122106A (ru) | Буферы для стабилизации лентивирусных препаратов | |
| IL297514A (en) | Vectors and methods for in vivo transduction | |
| IL297547A (en) | Therapeutic interventional particles for the corona virus | |
| US12305186B2 (en) | Methods for expanding SARS-COV2-antigen-specific t cells, compositions and uses related thereto | |
| JPWO2019232503A5 (https=) | ||
| HRP20230457T1 (hr) | Pripravci i postupci za selektivnu ekspresiju kimernih antigenskih receptora | |
| US20210095029A1 (en) | Compositions and methods for treating cancer | |
| JPWO2020033927A5 (https=) | ||
| CN110511912B (zh) | 免疫细胞的功能调节 | |
| JPWO2022178367A5 (https=) | ||
| CA3164666A1 (en) | Bcma-directed cellular immunotherapy compositions and methods | |
| KR20210126008A (ko) | 세포 면역 치료의 조합 | |
| WO2021057906A1 (zh) | 表达il-15的免疫效应细胞 | |
| JPWO2018073393A5 (https=) | ||
| JPWO2021041806A5 (https=) | ||
| JP2019531742A5 (https=) | ||
| US11701385B2 (en) | Modulation of cell function for immunotherapy | |
| JPWO2022241036A5 (https=) | ||
| JPWO2021231505A5 (https=) |